Accelerate Next Generation & Differentiated Therapies for Obesity & Beyond

The 3rd GLP-1 Based Therapeutics Summit came at a defining moment as the industry transitions from the first wave of clinical success to a "billion-dollar pivot" toward multi-organ protection and specialized care. As the flagship cardiometabolic summit focused on clinical and commercial GLP-1 drug development, this forum provided the strategic intelligence required to navigate a landscape shifting decisively toward advanced combination therapies and the ambitious pursuit of indications like Alzheimer’s, Parkinson’s, and cardiorenal protection.

2026’s summit was essential for mastering a market where simple monotherapy is no longer enough to win, instead, the focus is now on overcoming the "tolerability wall" through novel oral programs and targeted delivery systems like pancreatic gene therapy. The importance of this gathering is further underscored by the urgent need to preserve lean muscle mass and optimize safety profiles, ensuring new treatments offer healthier, sustainable long-term outcomes.

With Novo Nordisk joining a distinguished speaker faculty that already included industry giants like Eli Lilly, AstraZeneca, and Merck, the summit served as the global engine for de-risking high-investment multi-target therapeutics through advanced pharmacometric modeling and adaptive trial designs. As major approvals create massive franchises, this was the definitive platform for identifying the next growth areas in women’s health and addiction medicine, defining the future of metabolic health for millions worldwide.